Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.

PMID:
23235682
2.

Laquinimod for multiple sclerosis.

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S.

Cochrane Database Syst Rev. 2013 Aug 6;8:CD010475. doi: 10.1002/14651858.CD010475.pub2. Review.

PMID:
23922214
3.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;12:CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
4.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
5.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;4:CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
6.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Zhou H, Han W, Zhang S.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009130. doi: 10.1002/14651858.CD009130.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;12:CD009130.

PMID:
22161445
7.

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.

Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.

Cochrane Database Syst Rev. 2013 Jun 6;6:CD008933. doi: 10.1002/14651858.CD008933.pub2. Review.

PMID:
23744561
8.

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G.

Cochrane Database Syst Rev. 2015 Sep 18;9:CD011381. doi: 10.1002/14651858.CD011381.pub2. Review.

PMID:
26384035
9.

Mitoxantrone for multiple sclerosis.

Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G.

Cochrane Database Syst Rev. 2013 May 31;5:CD002127. doi: 10.1002/14651858.CD002127.pub3. Review.

PMID:
23728638
10.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang LN, Zhan S, Xia Y.

Cochrane Database Syst Rev. 2013 Dec 23;12:CD008127. doi: 10.1002/14651858.CD008127.pub4. Review.

PMID:
24363032
11.

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group.

Lancet Neurol. 2014 Oct;13(10):977-86. doi: 10.1016/S1474-4422(14)70191-7. Epub 2014 Sep 2.

PMID:
25192851
12.

Pharmacological treatment for memory disorder in multiple sclerosis.

He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 17;12:CD008876. doi: 10.1002/14651858.CD008876.pub3. Review.

PMID:
24343792
13.

Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.

Brunetti L, Wagner ML, Maroney M, Ryan M.

Ann Pharmacother. 2013 Sep;47(9):1153-60. doi: 10.1177/1060028013500647. Review.

PMID:
24259730
14.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
15.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan SY, Xia Y.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD008127. doi: 10.1002/14651858.CD008127.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;12:CD008127.

PMID:
22513956
16.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
17.

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

Thomas RH, Wakefield RA.

Am J Health Syst Pharm. 2015 Jan 1;72(1):25-38. doi: 10.2146/ajhp140023. Review.

PMID:
25511835
18.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
19.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
20.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;7:CD009333. doi: 10.1002/14651858.CD009333.pub2. Review.

PMID:
25062935
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk